Cardiothoracic & vascular anesthesia
Perioperative Renin–Angiotensin System Inhibitors Improve Major Outcomes of Heart Failure Patients Undergoing Cardiac Surgery: A Propensity-Adjusted Cohort Study
Main finding · 30-day mortalityResult — go to the resultOdds ratio 0.556 95% CI 0.405–0.763Authors' conclusion
Pre- and postoperative use of RASi was associated with better outcomes for the patients who have HF and undergo CABG and/or valve surgeries.
Study context
- Population
- Patients with heart failure (HF) undergoing CABG and/or valve surgery at multiple hospitals, STS database, 2001–2015
- Participants
- 2,338 patients
- Exposure
- Perioperative Renin Angiotensin System Inhibitors (RASi) vs no RASi
- Outcome
- 30-day mortality
- Follow-up
- 30 days
Methodological detailsmulticentre registry, propensity score and instrumental variable adjustment
- Multicentre registry
- Propensity score and instrumental variable adjustment
Main finding
As reported in the abstract
Odds ratio
0.556
95% CI 0.405–0.763
P < 0.0001
PreRASi vs No-RASi
OR 0.556 (95% CI 0.405–0.763); P < 0.0001
Observational data: associations, not effects.
Further findings
| Outcome | OR (95% CI) | P value | |
|---|---|---|---|
| StrokePreRASi vs No-RASi | 0.585 (0.355–0.962) | P = 0.035 | |
| Renal failurePreRASi vs No-RASi | 0.663 (0.493–0.894) | P = 0.007 | |
| 0.20.5125Odds ratio (log scale) |
| Outcome | P value |
|---|---|
| 6-year mortality · 6 yearsPreRASi vs No-RASi · reduced mortality | P = 0.0137 |
| 6-year mortality · 6 yearsPostRASi vs No-RASi · reduced mortality | P = 0.007 |
Original publication
Perioperative Renin–Angiotensin System Inhibitors Improve Major Outcomes of Heart Failure Patients Undergoing Cardiac Surgery: A Propensity-Adjusted Cohort Study. Ann Surg. Published 15 February 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →